Bioventus commenced U.S. launch of GELSYN-3™ three-injection hyaluronic acid for relief of pain associated with knee osteoarthritis. The regimen is intended to relieve pain for up to 6 months.
Bioventus acquired exclusive U.S. distribution rights for GELSYN from Institut Biochimique in 1Q16. The product had received FDA premarket approval in 2014.
Review Exhibit 115, the Viscosupplement Product Landscape, in THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT® for a matrix of products cleared and number of injections for various applications around the world.
Bioventus commenced U.S. launch of GELSYN-3™ three-injection hyaluronic acid for relief of pain associated with knee osteoarthritis. The regimen is intended to relieve pain for up to 6 months.
Bioventus acquired exclusive U.S. distribution rights for GELSYN from Institut Biochimique in 1Q16. The product had received FDA premarket approval in...
Bioventus commenced U.S. launch of GELSYN-3™ three-injection hyaluronic acid for relief of pain associated with knee osteoarthritis. The regimen is intended to relieve pain for up to 6 months.
Bioventus acquired exclusive U.S. distribution rights for GELSYN from Institut Biochimique in 1Q16. The product had received FDA premarket approval in 2014.
Review Exhibit 115, the Viscosupplement Product Landscape, in THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT® for a matrix of products cleared and number of injections for various applications around the world.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
